Osamu Maeda

13PUBLICATIONS
36CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 11, 2026
Impact of Dyslipidemia on Clinical Outcomes Among Cancer Patients Treated With Immune Checkpoint Inhibitors.

|Aug 27, 2026
Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G.

|Jun 29, 2026
Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Controlled Trial (NUPAT-01).

|May 21, 2026
Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third- or Later-Line Chemotherapy for CLDN18.2-Positive and HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol.

|Mar 08, 2026
FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study.

Kazuyuki Mizuno, Takuya Ishikawa, Takanori Ito

|Jul 02, 2025
Pazopanib and antacids: insights from the WHO pharmacovigilance database.

Kazuki Nishida, Yao Liang, Osamu Maeda

Pageof 3

Frequent Collaborators

5 joint publications

Yuichi Ando

3 joint publications

Kazuki Nishida

2 joint publications

Kazushi Miyata

2 joint publications

Mitsuro Kanda